Polyrizon's NASARIX™ Allergy Blocker Successfully Completes Biocompatibility Program
PLRZ has more than doubled off its 52-week low of $2.88 on elevated volume (2.6× avg).
Summary
Polyrizon's NASARIX™ Allergy Blocker successfully completed its biocompatibility program, clearing a major safety hurdle for its progression to human clinical trials and potential commercialization.
Key Events · Product Development and Regulatory · PLRZ
-
NASARIX™ Biocompatibility Program Success
The NASARIX™ Allergy Blocker nasal spray successfully completed its comprehensive biocompatibility evaluation program, with all biological safety tests meeting acceptance criteria.
-
Key Safety Endpoints Met
Evaluated endpoints included cytotoxicity, sensitization, irritation, pyrogenicity, and acute systemic toxicity, all demonstrating a strong safety profile in accordance with ISO 10993 and FDA guidance.
-
Advancing Clinical & Regulatory Pathway
This achievement is a significant milestone, strengthening the non-clinical package and supporting the product's progression towards first-in-human clinical trials and potential commercialization.
Analysis · PLRZ · Industrial Applications And Services
Polyrizon, a development-stage biotech, announced that its NASARIX™ Allergy Blocker nasal spray successfully passed all biological safety tests, meeting international standards. This critical milestone de-risks the product's safety profile and is a significant step towards advancing its clinical and regulatory pathway, following recent news of IRB approval and securing clinical trial sites.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PLRZ was trading at $13.80 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $28.8M. The 52-week trading range was $2.88 to $18.20. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.